![]() |
Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) DCF Valuation
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) Bundle
Evaluate Chengdu Kanghong Pharmaceutical Group Co., Ltd's financial outlook like an expert! This (002773SZ) DCF Calculator provides you with pre-filled financial data and the flexibility to modify revenue growth, WACC, margins, and other critical assumptions to align with your predictions.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3,257.4 | 3,295.4 | 3,605.3 | 3,389.0 | 3,957.5 | 4,168.6 | 4,391.1 | 4,625.4 | 4,872.2 | 5,132.2 |
Revenue Growth, % | 0 | 1.17 | 9.4 | -6 | 16.77 | 5.34 | 5.34 | 5.34 | 5.34 | 5.34 |
EBITDA | 932.1 | -396.4 | 545.9 | 1,094.5 | 1,388.7 | 826.3 | 870.4 | 916.9 | 965.8 | 1,017.3 |
EBITDA, % | 28.61 | -12.03 | 15.14 | 32.3 | 35.09 | 19.82 | 19.82 | 19.82 | 19.82 | 19.82 |
Depreciation | 95.6 | 121.5 | 150.9 | 161.7 | 222.6 | 176.8 | 186.2 | 196.2 | 206.6 | 217.7 |
Depreciation, % | 2.94 | 3.69 | 4.19 | 4.77 | 5.62 | 4.24 | 4.24 | 4.24 | 4.24 | 4.24 |
EBIT | 836.4 | -517.9 | 395.0 | 932.9 | 1,166.1 | 649.5 | 684.2 | 720.7 | 759.2 | 799.7 |
EBIT, % | 25.68 | -15.72 | 10.95 | 27.53 | 29.46 | 15.58 | 15.58 | 15.58 | 15.58 | 15.58 |
Total Cash | 2,283.7 | 3,327.7 | 3,138.9 | 3,685.4 | 4,702.1 | 3,811.6 | 4,014.9 | 4,229.2 | 4,454.8 | 4,692.6 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 434.5 | 346.2 | 204.6 | 160.7 | 160.4 | 319.4 | 336.5 | 354.4 | 373.3 | 393.3 |
Account Receivables, % | 13.34 | 10.51 | 5.68 | 4.74 | 4.05 | 7.66 | 7.66 | 7.66 | 7.66 | 7.66 |
Inventories | 263.1 | 239.6 | 295.6 | 331.0 | 403.6 | 362.8 | 382.1 | 402.5 | 424.0 | 446.6 |
Inventories, % | 8.08 | 7.27 | 8.2 | 9.77 | 10.2 | 8.7 | 8.7 | 8.7 | 8.7 | 8.7 |
Accounts Payable | 240.3 | 288.9 | 343.1 | 409.5 | 344.0 | 387.2 | 407.8 | 429.6 | 452.5 | 476.6 |
Accounts Payable, % | 7.38 | 8.77 | 9.52 | 12.08 | 8.69 | 9.29 | 9.29 | 9.29 | 9.29 | 9.29 |
Capital Expenditure | -962.9 | -617.1 | -569.4 | -355.2 | -138.9 | -650.9 | -685.6 | -722.2 | -760.7 | -801.3 |
Capital Expenditure, % | -29.56 | -18.72 | -15.79 | -10.48 | -3.51 | -15.61 | -15.61 | -15.61 | -15.61 | -15.61 |
Tax Rate, % | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 |
EBITAT | 719.3 | -269.0 | 422.7 | 811.9 | 987.3 | 532.1 | 560.5 | 590.4 | 622.0 | 655.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -605.3 | -604.2 | 144.1 | 693.4 | 933.2 | -17.0 | 45.4 | 47.8 | 50.4 | 53.1 |
WACC, % | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 | 5.31 |
PV UFCF | ||||||||||
SUM PV UFCF | 147.7 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 54 | |||||||||
Terminal Value | 1,634 | |||||||||
Present Terminal Value | 1,261 | |||||||||
Enterprise Value | 1,409 | |||||||||
Net Debt | -4,700 | |||||||||
Equity Value | 6,109 | |||||||||
Diluted Shares Outstanding, MM | 916 | |||||||||
Equity Value Per Share | 6.67 |
What You Will Receive
- Genuine 002773SZ Financial Data: Includes both historical and projected figures for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Instant Calculations: Automatically computes intrinsic value and NPV in real-time.
- Scenario Simulation: Explore various scenarios to assess the future performance of Chengdu Kanghong Pharmaceutical.
- User-Friendly Interface: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- Comprehensive KHP Financial Data: Includes historical financial performance and future projections for Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773SZ).
- Customizable Parameters: Tailor factors such as revenue growth, profit margins, WACC, tax rates, and capital expenditures to your needs.
- Interactive Valuation Model: Automatically refreshes Net Present Value (NPV) and intrinsic value based on your tailored inputs.
- Scenario Analysis: Develop various forecast scenarios to explore different valuation possibilities.
- Intuitive Interface: Designed for ease of use, catering to both professionals and beginners.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Chengdu Kanghong Pharmaceutical Group Co., Ltd's [002773SZ] pre-filled financial data and forecasts.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and apply the results to inform your investment decisions.
Why Opt for This Calculator?
- User-Friendly Design: Perfectly tailored for both novices and seasoned professionals.
- Customizable Inputs: Easily adjust parameters to suit your financial analysis.
- Real-Time Updates: Instantly observe changes to Chengdu Kanghong Pharmaceutical Group Co., Ltd’s valuation as you modify inputs.
- Pre-Configured: Comes equipped with Chengdu Kanghong Pharmaceutical Group Co., Ltd's actual financial data for expedited analysis.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed decisions.
Who Can Benefit from Our Product?
- Investors: Make informed decisions with our advanced valuation tool tailored for (002773SZ).
- Financial Analysts: Streamline your workflow with a customizable DCF model specifically designed for (002773SZ).
- Consultants: Effortlessly modify the template for client presentations or reports regarding (002773SZ).
- Finance Enthusiasts: Enhance your grasp of valuation methods through practical, real-world applications related to (002773SZ).
- Educators and Students: Utilize this resource as a hands-on learning aid in finance courses focusing on (002773SZ).
Components of the Template
- Pre-Filled Data: Features Chengdu Kanghong Pharmaceutical Group Co., Ltd's historical financials and projections.
- Discounted Cash Flow Model: An editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A specialized worksheet for WACC calculations based on user-defined inputs.
- Key Financial Ratios: Assess Chengdu Kanghong's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily adjust revenue growth, margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing essential valuation outputs.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.